Cargando…

Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a malignant lethal tumor and both cancer stem cells (CSCs) and metabolism reprogramming have been proven to play indispensable roles in HCC. This study aimed to reveal the connection between metabolism reprogramming and the stemness characteristics of HCC, establish...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuxin, Wan, Xueshuai, Du, Shunda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445950/ https://www.ncbi.nlm.nih.gov/pubmed/37622118 http://dx.doi.org/10.3389/fimmu.2023.1100100

Ejemplares similares

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
por: Cai, Jialiang, et al.
Publicado: (2022)

A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses
por: Cai, Guangzhen, et al.
Publicado: (2022)

Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma
por: Liu, Tao, et al.
Publicado: (2023)

Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians
por: Deng, Kaige, et al.
Publicado: (2023)

Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma
por: Tang, Yuqin, et al.
Publicado: (2022)

Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
por: Hong, Ting, et al.
Publicado: (2022)

Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma
por: Sun, Liang, et al.
Publicado: (2023)

Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma
por: Zhu, Jinfeng, et al.
Publicado: (2023)

A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses
por: Li, Jia, et al.
Publicado: (2022)

A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma
por: Chang, Wuguang, et al.
Publicado: (2023)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer
por: Xu, Yan, et al.
Publicado: (2023)

Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis
por: Yan, Zongcai, et al.
Publicado: (2021)

Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer
por: Cui, Hanxiao, et al.
Publicado: (2023)

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
por: Chen, Lin, et al.
Publicado: (2021)

Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma
por: Li, Yue, et al.
Publicado: (2022)

Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
por: Wang, Ning, et al.
Publicado: (2023)

Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm
por: Wang, Tao, et al.
Publicado: (2022)

A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma
por: Li, Qilin, et al.
Publicado: (2022)

Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy
por: Yu, Lihua, et al.
Publicado: (2022)

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma
por: Zhang, Xin, et al.
Publicado: (2023)

Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma
por: Xin, Hongjie, et al.
Publicado: (2023)

Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
por: Jiang, Silin, et al.
Publicado: (2023)

Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature
por: Zhang, Ze, et al.
Publicado: (2022)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis
por: Shu, Jianfeng, et al.
Publicado: (2023)

Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
por: Chen, Xiaokun, et al.
Publicado: (2023)

Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy
por: Chiang, Jason, et al.
Publicado: (2023)

A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
por: Fu, Xing, et al.
Publicado: (2022)

A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
por: Yuan, Jingsheng, et al.
Publicado: (2022)

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy
por: Wang, Zheng, et al.
Publicado: (2022)

A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts
por: Ren, Qianhe, et al.
Publicado: (2023)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma
por: Yu, Xue, et al.
Publicado: (2022)

Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma
por: Guo, Yuanyuan, et al.
Publicado: (2022)

Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
por: An, Bingzheng, et al.
Publicado: (2022)

Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma
por: Zhu, Jinfeng, et al.
Publicado: (2022)

Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma
por: Liu, Jichang, et al.
Publicado: (2022)

Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma
por: Xu, Zhijie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ln1nqb3mmtrq398vrmv8ckvj8